Sprycel® Effective for CNS Philadelphia Chromosome-positive Leukemia (7/29/2008)
Researchers from Europe have reported that Sprycel® (dasatinib) is effective therapy for patients with Philadelphia chromosome-positive (Ph-positive) leukemia that involves the central nervous system (CNS). The details of this study appeared in an early online publication in Blood on May 13, 2008.

Long-term Results of Fludara®, Cytoxan®, and Rituxan® for CLL (7/29/2008)
Researchers from the M.D. Anderson Cancer Center have reported six-year follow-up data on 234 patients with chronic lymphocytic leukemia (CLL) treated with Fludara® (fludarabine), Cytoxan® (cyclophosphamide), and Rituxan® (rituximab) (FCR). The details of this study appeared in an early online publication in Blood on April 14, 2008.

Lumiliximab and FCR Promising for Relapsed CLL (6/26/2008)
Researchers from M.D. Anderson Cancer Center have reported that a regimen of lumilixmab, fludarabine, cyclophosphamide, and rituximab (L-FCR) is effective for the treatment of patients with relapsed CLL. The details of this Phase I/II study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia (6/25/2008)
Researchers from Ohio State University have reported that flavopiridol has “pronounded” activity in treating patients with relapsed chronic lymphocytic leukemia (CLL). The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Sprycel® Effective for Patients with Newly Diagnosed CML (6/24/2008)
Researchers from the M.D. Anderson Cancer Center have reported that Sprycel® (dasatinib) produces rapid and complete cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML). These data were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.